+Timos Papagatsias

Monday, 21 February 2011

It all started with EpiMatrix...

Leave a Comment
Applying computational approaches to immunogen selection and modification has set new standards in vaccine design. Consider codon optimization, a method which allowed scientists to circumvent codon usage bias in order to achieve high levels of difficult-to-express proteins outside their native hosts. Codon optimization has helped immensely in the development of HIV prototype vaccines where viral genes (gag, env, pol etc.) were expressed in the absence of the Rev-RRE system. Achieving efficient expression of a...
Read More...

Tuesday, 8 February 2011

Immune Design steps up and gets noticed…again...and again!

Leave a Comment
Back in July, Immune Design raised $32 million in a Series B financing; that’s quite a bit of money and brings the total up to $50 million since 2008. Amongst the leading investors we can see ProQuest Investments (who also have in their portfolio companies like Aerovance, who develops asthma-combating drugs, and  Somalogic, who develops novel diagnostics tools for oncology, neurology and CV diseases), The Column Group, Versant Ventures and Alta Partners.Now the company is making waves once again by...
Read More...